Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 15/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.39 |
| ▸ | WNT3A | P56704 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758316 | 1.00 | PIK3CA (0.48) | PIK3CAPIK3CGNPC1RAB9AGPR183 | |
| SCHEMBL31275859 | 1.00 | PIK3CA (0.48) | PIK3CAPIK3CGNPC1RAB9AGPR183 | |
| SCHEMBL14570174 | 1.00 | PIK3CA (0.48) | PIK3CAPIK3CGNPC1RAB9AGPR183 | |
| SCHEMBL4013347 | 0.82 | TSHR (0.45) | NPC1RAB9AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4013346 | 0.82 | TSHR (0.45) | NPC1RAB9AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL18002576 | 0.76 | PIK3CA (0.51) | PIK3CAPIK3CGNPC1RAB9AGPR183 | |
| SCHEMBL497425 | 0.76 | PIK3CA (0.55) | PIK3CAPIK3CGNPC1RAB9AGPR183 | |
| SCHEMBL6142463 | 0.74 | PIK3CA (0.41) | PIK3CAPIK3CGNPC1RAB9AGPR183 | |
| SCHEMBL7267886 | 0.73 | PIK3CA (0.41) | PIK3CAPIK3CGNPC1RAB9AGPR183 | |
| SCHEMBL7267880 | 0.73 | PIK3CA (0.41) | PIK3CAPIK3CGNPC1RAB9AGPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | PIK3CA 4651/4885PIK3CG 4358/4885NPC1 790/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | PIK3CA 4663/4885PIK3CG 4239/4885NPC1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.